TRCT
OBIO icon

Tower Research Capital (TRC)’s Orchestra BioMed OBIO Stock Holding History

Tower Research Capital (TRC)’s Portfolio OBIO Stock Details OBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.33K Sell
547
-99
-15% -$421 ﹤0.01% 4496
2025
Q4 		$2.68K Buy
+646
New +$2.61K ﹤0.01% 4484
2025
Q3 		– Sell
-27,922
Closed -$74.8K – 5494
2025
Q2 		$74.8K Buy
27,922
+25,666
+1,138% +$74.9K ﹤0.01% 2622
2025
Q1 		$9.66K Sell
2,256
-67
-3% -$333 ﹤0.01% 3747
2024
Q4 		$9.29K Buy
2,323
+407
+21% +$2.19K ﹤0.01% 3917
2024
Q3 		$9.85K Sell
1,916
-2,969
-61% -$19.4K ﹤0.01% 3828
2024
Q2 		$39.8K Buy
4,885
+3,174
+186% +$18.4K ﹤0.01% 3270
2024
Q1 		$9.02K Sell
1,711
-757
-31% -$5.13K ﹤0.01% 3915
2023
Q4 		$22.5K Buy
2,468
+911
+59% +$6.22K ﹤0.01% 3576
2023
Q3 		$13.6K Buy
1,557
+1,012
+186% +$6.8K ﹤0.01% 3772
2023
Q2 		$3.81K Sell
545
-363
-40% -$5.51K ﹤0.01% 5020
2023
Q1 		$18K Sell
908
-1,215
-57% -$14.1K ﹤0.01% 3568
2022
Q4 		$21K Hold
2,123
– – ﹤0.01% 3096
2022
Q3 		$21K Buy
2,123
+984
+86% +$9.76K ﹤0.01% 3898
2022
Q2 		$11K Buy
1,139
+54
+5% +$537 ﹤0.01% 4383
2022
Q1 		$11K Buy
1,085
+888
+451% +$8.77K ﹤0.01% 4194
2021
Q4 		$2K Buy
197
+50
+34% +$493 ﹤0.01% 5644
2021
Q3 		$1K Sell
147
-545
-79% -$5.38K ﹤0.01% 5510
2021
Q2 		$7K Buy
692
+147
+27% +$1.52K ﹤0.01% 4562
2021
Q1 		$6K Buy
+545
New +$6.64K ﹤0.01% 4600

Other funds holding OBIO

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
PBM
Propel Bio Management Los Angeles, California $159M AUM 60.94% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Tower Research Capital (TRC)'s OBIO Position: Q1 2026 in Review

Tower Research Capital (TRC) reduced its Orchestra BioMed (OBIO) stake by 15% in Q1 2026, selling an estimated $421 and leaving 547 shares worth $2.33K. The position accounts for ﹤0.01% of the portfolio, ranked #4496.

Tower Research Capital (TRC) first reported a position in OBIO in Q1 2021 and has held it in 20 quarters since. The position peaked at $74.8K in Q2 2025. 65 funds tracked by Wall St. Rank hold OBIO as of Q1 2026.

  • Tower Research Capital (TRC) held 547 shares of Orchestra BioMed worth $2.33K as of Q1 2026.
  • Tower Research Capital (TRC) sold 99 Orchestra BioMed shares in Q1 2026, an estimated $421.
  • Orchestra BioMed made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q1 2026, its #4496 holding.
  • Tower Research Capital (TRC) first reported a position in Orchestra BioMed in Q1 2021 and has held it in 20 quarters since.
  • Tower Research Capital (TRC)'s Orchestra BioMed position peaked at $74.8K in Q2 2025.
  • 65 funds tracked by Wall St. Rank held Orchestra BioMed as of Q1 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q1 2026, filed 15 May 2026.